1. Clinical Overview
Vecuronium bromide is a non-depolarizing neuromuscular blocking agent of the aminosteroid class, used as an adjunct to general anesthesia to provide skeletal muscle relaxation during surgery or mechanical ventilation. It acts as a competitive antagonist at the nicotinic acetylcholine receptors of the neuromuscular junction. In the Indian context, it is a critical drug in the operating theatre and ICU settings, available as a lyophilized powder requiring reconstitution.
| Onset | Duration | Bioavailability |
|---|---|---|
| 2-3 minutes (after an intubating dose of 0.08-0.1 mg/kg IV) | 25-40 minutes (after an intubating dose) | 100% (Intravenous administration only) |
2. Mechanism of Action
Vecuronium competitively and reversibly antagonizes the action of acetylcholine at the postjunctional nicotinic receptors of the skeletal muscle motor endplate. This prevents depolarization of the muscle cell membrane and inhibits muscular contraction.
3. Indications & Uses
- Adjunct to general anesthesia to facilitate endotracheal intubation
- Provision of skeletal muscle relaxation during surgical procedures
4. Dosage & Administration
Adult Dosage: Initial intubating dose: 0.08 to 0.1 mg/kg IV bolus. Maintenance dose: 0.01 to 0.015 mg/kg IV, administered when twitch response returns to 25% of control. Continuous infusion: 0.8 to 1.2 mcg/kg/min after a loading dose.
Administration: For 20mg vial: Reconstitute with 10-20 mL of Water for Injection, 0.9% Sodium Chloride, or 5% Dextrose to yield 2 mg/mL or 1 mg/mL solution. Administer as a slow IV bolus over 30-60 seconds. NEVER administer via IM route. Use must be accompanied by adequate sedation/analgesia and continuous monitoring of vital signs and neuromuscular function (train-of-four monitoring).
5. Side Effects
Common side effects may include:
- Prolonged neuromuscular blockade beyond clinical need
- Inadequate or insufficient muscle relaxation
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Volatile Inhalational Anesthetics (Isoflurane, Sevoflurane, Desflurane) | Potentiates neuromuscular blockade, reducing vecuronium requirement by 20-50%. | Major |
| Aminoglycosides (Gentamicin, Amikacin), Polymyxins | Potentiate blockade, may cause prolonged apnea. | Major |
| Magnesium Sulfate | Potentiates blockade, requiring significant dose reduction. | Major |
| Succinylcholine | Prior use may enhance the depth and duration of vecuronium blockade. | Moderate |
| Calcium Channel Blockers (Verapamil, Diltiazem) | May enhance neuromuscular blockade. | Moderate |
| Corticosteroids (chronic use) | May cause resistance to vecuronium in ICU patients. | Moderate |
| Phenytoin, Carbamazepine | May cause resistance, requiring higher doses. | Moderate |
7. Patient Counselling
- Do inform your anesthesiologist about all medical conditions, especially liver/kidney disease, muscle disorders, and allergies.
- Do report any history of difficult intubation or malignant hyperthermia in family.
- Do not expect to have any muscle control during drug effect.
- Do not consume food prior to surgery as directed.
8. Toxicology & Storage
Overdose: Prolonged and profound neuromuscular blockade resulting in apnea, respiratory insufficiency or arrest, and skeletal muscle flaccidity. Bradycardia or tachycardia may occur.
Storage: Store unopened vials at 2°C to 8°C (refrigerated). Protect from light. After reconstitution with Water for Injection or 0.9% NaCl, the solution is stable for 24 hours at 2°C to 8°C or 5 hours at room temperature (15-25°C). Do not freeze. Discard any unused portion.